Pressure builds on prescription drug middlemen as the companies see stocks and profits rise

A wide group of plaintiffs in a national insulin pricing lawsuit are seeking to add a group of shadowy companies set up by health conglomerates as they argue that two layers of prescription drug middlemen are illegally inflating the price of the lifesaving medicines.